Items where authors include "Howard, H."

Article

Vasudev, N.S. orcid.org/0000-0001-8470-7481, Ainsworth, G., Brown, S. et al. (24 more authors) (2023) Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM). Journal of Clinical Oncology. ISSN 0732-183X

Vasudev, N.S. orcid.org/0000-0001-8470-7481, Ainsworth, G. orcid.org/0000-0002-9952-8440, Brown, S. orcid.org/0000-0002-7975-7537 et al. (24 more authors) (2023) Standard versus modified ipilimumab, in combination with nivolumab, in advanced renal cell carcinoma: a randomized phase II trial (PRISM). Journal of Clinical Oncology. JCO2300236. ISSN 0732-183X

Coen, O., Corrie, P., Marshall, H. et al. (17 more authors) (2021) The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma. BMC Cancer, 21 (1). 761. ISSN 1471-2407

Craig, Z., Swain, J., Batman, E. et al. (16 more authors) (2020) NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC). BMJ Open, 10 (2). e034527. ISSN 2044-6055

Collinson, F.J., Gregory, W.M., McCabe, C. et al. (11 more authors) (2012) The STAR trial protocol: a randomised multi-stage phase II/III study of Sunitinib comparing temporary cessation with allowing continuation, at the time of maximal radiological response, in the first-line treatment of locally advanced/metastatic Renal Cancer. BMC Cancer, 12. 598. ISSN 1471-2407